RESUMEN
Delirium is an acute disorder of fluctuating attention and awareness with cardinal features that allow it to be positively distinguished from other causes of an acute confusional state. These features include fluctuations, prominent inattentiveness with other cognitive deficits, a change in awareness and visual hallucinations. We describe a framework for diagnosing delirium, noting the need to consider certain caveats and differential diagnoses. Delirium is a clinical diagnosis where a thorough history and clinical examination are much more helpful diagnostically than any single test or combination of tests.
Asunto(s)
Trastornos del Conocimiento , Disfunción Cognitiva , Delirio , Humanos , Delirio/diagnóstico , Delirio/etiología , Delirio/psicología , Trastornos del Conocimiento/diagnóstico , Diagnóstico Diferencial , Disfunción Cognitiva/diagnósticoRESUMEN
Delirium is a common condition affecting hospital inpatients, including those having surgery and on the intensive care unit. Delirium is also common in patients with COVID-19 in hospital settings, and the occurrence is higher than expected for similar infections. The short-term outcomes of those with COVID-19 delirium are similar to that of classical delirium and include increased length of stay and increased mortality. Management of delirium in COVID-19 in the context of a global pandemic is limited by the severity of the syndrome and compounded by the environmental constraints. Practical management includes effective screening, early identification and appropriate treatment aimed at minimising complications and timely escalation decisions. The pandemic has played out on the national stage and the effect of delirium on patients, relatives and healthcare workers remains unknown but evidence from the previous SARS outbreak suggests there may be long-lasting psychological damage.
Asunto(s)
COVID-19/epidemiología , COVID-19/psicología , Delirio/epidemiología , Delirio/psicología , Personal de Salud/psicología , Encéfalo/metabolismo , COVID-19/metabolismo , COVID-19/terapia , Delirio/metabolismo , Delirio/terapia , Humanos , Mediadores de Inflamación/metabolismo , Unidades de Cuidados Intensivos/tendenciasAsunto(s)
COVID-19/complicaciones , Trastornos Neurocognitivos/etiología , Complicaciones Posoperatorias/epidemiología , Anciano , Anciano de 80 o más Años , Anestesia/efectos adversos , Delirio/etiología , Delirio/psicología , Humanos , Trastornos Neurocognitivos/psicología , Complicaciones Posoperatorias/psicología , Factores de Riesgo , Procedimientos Quirúrgicos Operativos/efectos adversosRESUMEN
BACKGROUND: COVID-19 patients present with delirium during their hospitalization. AIMS: To assess the incidence of delirium in hospitalized COVID-19 patients and analyze the possible association with demographic, clinical, laboratory, and pharmacological factors. METHODS: COVID-19 patients were assessed for clinical signs of delirium and administered the assessment test for delirium and cognitive impairment (4AT) and the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) scales. RESULTS: Out of the 56 patients of our cohort, 14 (25.0%) experienced delirium. The use of low molecular weight heparin (LMWH) (enoxaparin 1 mg/kg/daily) was less frequent in patients with delirium (p = 0.004) and was accompanied by lower C reactive protein (CRP) levels (p = 0.006). DISCUSSION: The use of LMWH was associated with absence of delirium, independently of comorbidities and age. CONCLUSIONS: The use of LMWH may help preventing the occurrence of delirium in COVID-19 patients, with possible reduction of length of stay in the hospital and sequelae.
Asunto(s)
Anticoagulantes/uso terapéutico , COVID-19/complicaciones , Delirio/etiología , Delirio/prevención & control , Enoxaparina/uso terapéutico , Heparina de Bajo-Peso-Molecular/uso terapéutico , Anciano , Anciano de 80 o más Años , Proteína C-Reactiva/análisis , COVID-19/psicología , Trastornos del Conocimiento/etiología , Trastornos del Conocimiento/psicología , Estudios de Cohortes , Comorbilidad , Confusión/psicología , Delirio/psicología , Femenino , Humanos , Pacientes Internos , Tiempo de Internación , Masculino , Pruebas NeuropsicológicasAsunto(s)
COVID-19/complicaciones , COVID-19/psicología , Disfunción Cognitiva/etiología , Delirio/complicaciones , Delirio/psicología , Demencia/etiología , COVID-19/epidemiología , Disfunción Cognitiva/epidemiología , Enfermedad Crítica/epidemiología , Enfermedad Crítica/psicología , Delirio/epidemiología , Demencia/epidemiología , Dexmedetomidina/uso terapéutico , Estudios de Seguimiento , HumanosAsunto(s)
Cuidados Posteriores , Cuidados Críticos , Enfermedad Crítica , Delirio , Unidades de Cuidados Intensivos , Cuidados Posteriores/métodos , Cuidados Posteriores/normas , Cuidados Críticos/métodos , Cuidados Críticos/psicología , Cuidados Críticos/normas , Enfermedad Crítica/psicología , Enfermedad Crítica/terapia , Delirio/etiología , Delirio/psicología , Delirio/terapia , Necesidades y Demandas de Servicios de Salud , Humanos , Unidades de Cuidados Intensivos/organización & administración , Unidades de Cuidados Intensivos/normas , Salud Mental , Grupo de Atención al Paciente/organización & administración , Grupo de Atención al Paciente/normas , Mejoramiento de la Calidad , Sobrevivientes/psicologíaRESUMEN
Patients admitted with COVID-19 can develop delirium due to predisposing factors, isolation, and the illness itself. Standard delirium prevention methods focus on interaction and stimulation. It can be challenging to deliver these methods of care in COVID settings where it is necessary to increase patient isolation. This paper presents a typical clinical vignette of representative patients in a tertiary care hospital and how a medical team modified an evidence-based delirium prevention model to deliver high-quality care to COVID-19 patients. The implemented model focuses on four areas of delirium-prevention: Mobility, Sleep, Cognitive Stimulation, and Nutrition. Future studies will be needed to track quantitative outcome measures.
Asunto(s)
Enfermedad de Alzheimer/diagnóstico , Enfermedad de Alzheimer/terapia , COVID-19/prevención & control , Delirio/prevención & control , Anciano , Enfermedad de Alzheimer/psicología , COVID-19/epidemiología , COVID-19/psicología , Delirio/epidemiología , Delirio/psicología , Humanos , MasculinoAsunto(s)
COVID-19/complicaciones , COVID-19/psicología , Cognición/fisiología , Disfunción Cognitiva/etiología , Disfunción Cognitiva/psicología , Sobrevivientes/psicología , COVID-19/epidemiología , Disfunción Cognitiva/epidemiología , Delirio/epidemiología , Delirio/etiología , Delirio/psicología , Humanos , Factores de Riesgo , Factores de TiempoAsunto(s)
Delirio/prevención & control , Lectura , Voluntarios/estadística & datos numéricos , Enfermedad Crítica/psicología , Enfermedad Crítica/terapia , Delirio/complicaciones , Delirio/psicología , Humanos , Unidades de Cuidados Intensivos/organización & administración , Unidades de Cuidados Intensivos/estadística & datos numéricos , Unidades de Cuidados Intensivos/tendencias , Proyectos Piloto , Evaluación de Programas y Proyectos de Salud/métodos , Factores de Riesgo , Estadísticas no ParamétricasRESUMEN
BACKGROUND: The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged as one of the biggest health threats of our generation. A significant portion of patients are presenting with delirium and neuropsychiatric sequelae of the disease. Unique examination findings and responses to treatment have been identified. OBJECTIVE: In this article, we seek to provide pharmacologic and treatment recommendations specific to delirium in patients with COVID-19. METHODS: We performed a literature search reviewing the neuropsychiatric complications and treatments in prior coronavirus epidemics including Middle Eastern respiratory syndrome and severe acute respiratory syndrome coronaviruses, as well as the emerging literature regarding COVID-19. We also convened a work group of consultation-liaison psychiatrists actively managing patients with COVID-19 in our hospital. Finally, we synthesized these findings to provide preliminary pharmacologic recommendations for treating delirium in these patients. RESULTS: Delirium is frequently found in patients who test positive for COVID-19, even in the absence of respiratory symptoms. There appears to be a higher rate of agitation, myoclonus, abulia, and alogia. No data are currently available on the treatment of delirium in patients with COVID-19. Extrapolating from general delirium treatment, Middle Eastern respiratory syndrome/severe acute respiratory syndrome case reports, and our experience, preliminary recommendations for pharmacologic management have been assembled. CONCLUSIONS: COVID-19 is associated with neuropsychiatric symptoms. Low-potency neuroleptics and alpha-2 adrenergic agents may be especially useful in this setting. Further research into the pathophysiology of COVID-19 will be key in developing more targeted treatment guidelines.
Asunto(s)
Agonistas de Receptores Adrenérgicos alfa 2/uso terapéutico , Antipsicóticos/uso terapéutico , Encefalopatías/fisiopatología , Infecciones por Coronavirus/fisiopatología , Delirio/tratamiento farmacológico , Agonistas de Dopamina/uso terapéutico , Neumonía Viral/fisiopatología , Betacoronavirus , Encefalopatías/psicología , COVID-19 , Depresores del Sistema Nervioso Central/uso terapéutico , Infecciones por Coronavirus/psicología , Delirio/fisiopatología , Delirio/psicología , Moduladores del GABA/uso terapéutico , Humanos , Lorazepam/uso terapéutico , Melatonina/uso terapéutico , Pandemias , Neumonía Viral/psicología , Guías de Práctica Clínica como Asunto , SARS-CoV-2RESUMEN
BACKGROUND: Evidence of immune-mediated neurological syndromes associated with the severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection is limited. We therefore investigated clinical, serological and CSF features of coronavirus disease 2019 (COVID-19) patients with neurological manifestations. METHODS: Consecutive COVID-19 patients with neurological manifestations other than isolated anosmia and/or non-severe headache, and with no previous neurological or psychiatric disorders were prospectively included. Neurological examination was performed in all patients and lumbar puncture with CSF examination was performed when not contraindicated. Serum anti-gangliosides antibodies were tested when clinically indicated. RESULTS: Of the 349 COVID-19 admitted to our center between March 23rd and April 24th 2020, 15 patients (4.3%) had neurological manifestations and fulfilled the study inclusion/exclusion criteria. CSF examination was available in 13 patients and showed lymphocytic pleocytosis in 2 patients: 1 with anti-contactin-associated protein 2 (anti-Caspr2) antibody encephalitis and 1 with meningo-polyradiculitis. Increased serum titer of anti-GD1b antibodies was found in three patients and was associated with variable clinical presentations, including cranial neuropathy with meningo-polyradiculitis, brainstem encephalitis and delirium. CSF PCR for SARS-CoV-2 was negative in all patients. CONCLUSIONS: In SARS-Cov-2 infected patients with neurological manifestations, CSF pleocytosis is associated with para- or post-infectious encephalitis and polyradiculitis. Anti-GD1b and anti-Caspr2 autoantibodies can be identified in certain cases, raising the question of SARS-CoV-2-induced secondary autoimmunity.